Cardiff Oncology (CRDF) announced plans to advance the company’s lead program to the first-line setting of metastatic colorectal cancer and conduct its new CRDF-004 trial with study execution support from Pfizer (PFE) Ignite, a new end-to-end service for biotech companies.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRDF: